Pulmonary arteriovenous malformations (PAVMs) are most commonly seen in association with hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome [1] . Standard treatment is coil embolization, as PAVMs can cause stroke and cerebral abscesses [2] due to a paradoxical shunt, and pulmonary complications such as spontaneous hemothorax and hemoptysis. PAVM recanalization is an important finding that may lead to paradoxical embolism. Previous studies [3, 4] have demonstrated increased feeding artery diameter, low number of coils, use of oversized coils, and proximal coil placement within the feeding artery are associated with recanalization. Although anatomic and technical factors affecting recanalization have been extensively studied, there remains a lack of evidence regarding the effects of medication and pulmonary hypertension on PAVM recanalization.
Up to 28% [5, 6] of HHT patients are treated with antithrombotic medication (defined as antiplatelet agents or anticoagulants), but close clinical follow-up is required given the risk for worsening epistaxis [5, 6] . Primary indications for antithrombotic medication include cardiac arrhythmias (23%), venous thromboembolism (21%), stroke or transient ischemic attack (TIA) (19%), postoperative prophylaxis (17%), and cardiac problems (primary prevention 11%) [6] . The majority of patients on antithrombotics (57.3%) experienced worsening epistaxis, while 43% had no change or improved symptoms [5] . The hypothesis of this investigation is that antithrombotic use results in increased risk of PAVM recanalization. Given the frequent need for antithrombotics among HHT patients, it is imperative to understand their effect on PAVM embolization. The results will aid clinicians in understanding the risks and benefits of such therapy. The purpose of this investigation is to identify whether the use of antithrombotic medication is a significant predictor of recanalization in HHT patients with embolized PAVMs.
Methods

Study Population
This single-centre, retrospective cohort study was approved by the institutional review board. From 2005-2014, 114 consecutive patients with 202 embolized PAVMs were evaluated. Among them, 30 patients with 36 recanalized PAVMs underwent 42 embolizations. Inclusion criteria included the genetic diagnosis of HHT and the presence of PAVMs that underwent embolized. Exclusion criteria included patients with PAVMs who did not have a confirmed diagnosis of HHT. A retrospective analysis of computed tomography (CT), digital subtraction angiography, and clinical charts was performed. Clinical evaluation included a HHT specialist (fellowship-trained respirologist with >10 years running a provincial HHT clinic and research practice) obtained history and physical examination of all patients and routine screening for pulmonary and cerebral AVMs was performed. Baseline patient demographics were aggregated, including age at embolization, time from detection to embolization, and duration of imaging follow-up. Embolization-specific variables included number, location, angiographic characteristics, and details of embolization technique (number of coils, type). Clinical variables included antithrombotic use pre-and postembolization.
To adequately power the investigation, sample size analysis using inference of proportions was performed to determine the number of subjects needed to detect a significant (95% confidence) difference in proportions (antithrombotic use) with a desired power of 80%. A previous investigation at this institution demonstrated antithrombotic use in the recanalized group was 30%, compared with 15% in the nonrecanalized group [6] . As such, the presumed risk of recanalization with antithrombotic use was assumed to be twice the baseline risk. Power analysis determined a sample size of 110 is required to attain an adequately powered study and demonstrate statistically significant differences between groups.
Embolization Technique
All PAVMs were superselectively cannulated and embolization with coils was performed by a solitary interventional radiologist with 12 years of primary operator experience in PAVM embolization. Angiographic endpoint was cessation of contrast material flow through the PAVM. Pulmonary arterial pressures were obtained at the time of embolization. For embolization of recanalized PAVMs, whenever sufficient feeding artery length was available distal to the originally placed coils, an attempt was made to cross the coils and deposit additional embolic material distally. A coaxial catheter system was used to select the feeding artery of the PAVM, and then pushable fiber-lined coils were deployed within the feeding artery distal to the previously placed coils, within the original coils, or proximal to the previously placed coils when it is not technically feasible to deploy the coils distally. Angiographic endpoint was cessation of contrast material flow through the PAVM. Patients were not systemically heparinized for the embolization procedure. Follow-up noncontrast CT was performed 1-year postembolization, acquired during a single breath-hold in the supine position. Images were reconstructed at a slice thickness of 3.75 mm with 1.8 mm of overlap in a standard soft-tissue algorithm and a lung algorithm. Pre-and posttreatment CT scans were compared by a solitary interventional radiologist (who also performed all PAVM embolizations) to assess for persistence, change, or resolution of the nidus and draining vein components of the PAVM. According to the previously described CT criteria [7] , successful treatment is defined as complete resolution of the nidus and vein or decrease in size of the nidus and vein by at least 70%. Draining veins were measured as close as possible to the aneurysmal sac, where vessel walls were parallel, beyond any transitional dilation to the aneurysmal sac, if present. If the CT criteria were not met or there was diagnostic uncertainty, the patient proceeded to pulmonary digital subtraction angiography to assess for PAVM recanalization.
Definitions
Recanalization of a PAVM is defined as continued patency through the malformation after embolization, proven on digital subtraction angiography. Mechanisms of recanalization included recanalization, accessory vessel development, and bronchial artery supply. Recanalization referred to PAVMs that filled through the originally embolized arteries. Accessory growth refers to persistent flow through the malformation supplied by an accessory vessel that is not present on the initial angiographic examination. Bronchial artery supply referred to bronchial artery to pulmonary artery anastomoses distal to the site of embolization. Antithrombotic use is defined as use of antiplatelet agents or anticoagulation agents. Antithrombotic use pre-embolization is defined as regular (>3 months duration) antithrombotic use prior to embolization. Antithrombotic use postembolization is defined as antithrombotic use during embolization, or at any time after the embolization is complete (including duration of follow-up). A complex PAVM is defined as having 2 or more different segmental feeding arteries [3] . Peripheral PAVMs were defined as more than 4 cm away from the mediastinum in the short-axis dimension. Pulmonary hypertension is defined as a mean PA pressure >25 mm Hg obtained at angiography.
Statistical Analysis
All statistical analysis was performed using the Stata statistical software release 14 (StataCorp LP, College Station, TX, USA). All tests were performed as a 2-tailed analysis with a significance of (P < .05). Baseline patient characteristics in patients with recanalized PAVMs and patient with no recanalized PAVMs were compared using t tests for continuous measures and z tests to compare proportions. Proposed predictors of recanalization were analysed, comparing recanalized versus nonrecanalized PAVMs, using univariate logistic regression and multivariate regression. Patients with PAVMs that demonstrated recurrent recanalization were analysed using univariate logistic regression to determine if PA pressure or antithrombotic use is associated with recurrent recanalization. PA pressure was analysed as a continuous numerical variable (mm HG) and a binary dichotomous variable (the presence or absence of pulmonary hypertension). (Table 1) were not significantly different between the nonrecanalized and recanalized groups. There were no differences in mean pulmonary arterial pressure 
Results
Baseline Patient Demographics
Predictors of Recanalization
Logistic regression: univariate
Univariate logistic regression ( Antithrombotic postembolization is significantly associated with primary (OR 15.21; 95% CI 1.54-150.13; P ¼ .020) and recurrent recanalization (OR 6.40; 95% CI 1.31-31.26; P ¼ .02). Number of PAVMs is significantly associated with primary (OR 1.22; 95% CI 1.01-1.47; P ¼ .041) and recurrent recanalization (OR 25.30; 95% CI 2.91-1151.39; P ¼ .001). Absolute pulmonary artery pressure (OR 1.02; 95% CI 0.96-1.09; P ¼ .549) or the presence of pulmonary hypertension (OR 2.89; 95% CI 0.67-12.37) is not significantly associated with recanalization. Coil type or total number of coils placed is not significantly associated with recanalization ( Table 2) .
Logistic regression: multivariate
Multivariate regression of proposed predictors of recanalization (Table 3) shows antithrombotic use postembolization is a significant predictor of recanalization (t ¼ 2.64, P ¼ .010). Number of PAVMs is also a predictor of recanalization (t ¼ 2.85, P ¼ .006). Pulmonary hypertension is a significant predictor of recanalization (t ¼ 2.00, P ¼ .048). Coil type or total number of coils placed is not predictive of recanalization (Table 3) . 
Mechanisms of Recanalization and Antithrombotic Use
Recanalization is the mechanism of recanalization in 93% of the 30 patients with 36 recanalized PAVMs. An accessory pulmonary feeder artery is the mechanism of recanalization in 7% of cases. Recurrent recanalization occurred in 27% of recanalized PAVMs (n ¼ 8) and 4% of all patients with PAVMs. No patients were on multiple antithrombotic medications. A total of 70% of cases were anticoagulated to reduce stroke risk due to previous TIA or stroke. The antithrombotic used postembolization is acetylsalicylic acid (81 mg) in 70% of cases, clopidogrel (75 mg once daily in the setting of recent myocardial infarction or stroke) in 15%, warfarin (dosage unavailable) in 8%, and dalteparin (dosage unavailable) in 7%.
Discussion
Antithrombotic use postembolization is associated with and predicts solitary and recurrent PAVM recanalization in HHT. This provides new information for physicians and interventional radiologist to consider when prescribing antithrombotics for HHT patients. Current guidelines suggest that antithrombotics may be used in HHT patients when clinically indicated, with the caveat that it worsens epistaxis [2] . Recent investigations demonstrate 28.1% of HHT patients report use of antithrombotic therapy [5] , with a wide variation in side effect profiles with respect to hemorrhage. In this investigation, 13.2% of HHT patients with PAVMs had used antithrombotics during their follow-up, compared to 14% of all HHT patients in a previous study [6] .
Traditionally, the risks associated with antithrombotic use include worsening epistaxis and uncontrolled bleeding in spontaneous hemorrhage. However, the presence of a PAVM may increase the risk of stroke, TIA, and cerebral abscess [2] . Whether this applies and to what degree it applies to recanalized PAVMs has not been elucidated. Lee et al [7] reported 2 stokes in patients with known recanalization of their PAVM, which support the hypothesis that recanalized PAVMs may act as a shunt. Given that the indication for antithrombotic use for 70% of patients in this investigation is previous stroke or TIA, clinicians must weigh the risks of future stroke and TIA against the risks of worsening epistaxis, bleeding, and a recanalized PAVM. Currently, there is no clear recommendation for antithrombotic use for stroke or TIA from PAVMs, and this evidence lends further credence to the argument that the risk-benefit ratio does not favor their use for the specific management of stroke or TIA from PAVMs.
Antithrombotic use is likely underestimated in this investigation, as patients were not asked about antithrombotic use directly, but instead clinic records were retrospectively analysed. Clinic records are likely to underreport antithrombotic use, as they rely transcription and the dictating individual mentioning changes in medication, as well as the patient miscommunication. This underestimation might have decreased the statistical effect size of antithrombotic use on recanalization, and might have resulted in a less precise measurement (causing wide CIs).
The reperfusion incidence is 17%, comparable to previous studies (0%-22%) [4,7e12] . The most common mechanism of recanalization is recanalization of the occluded artery, and is seen in 63%-100% of recanalized PAVMs [10e15]. Other described mechanisms of recanalization include the development of accessory vessels [7] and rarely, bronchial artery hypertrophy [10] . The relative proportions of mechanisms of PAVM recanalization in this investigation support previous studies. Recanalization occurred in 93% of cases, and accessory feeder vessels developed in 7% of PAVMs. These findings speak to the generalizability of the results, as they are clearly concordant with the scientific literature. This study also demonstrated that patients with a larger number of PAVMs were more likely to develop recanalization. The reason for this is unknown, but may be associated with the degree of transforming growth factor b dysregulation [16] . This finding may also be spurious in nature, given that there are no clinical or angiographic reasons for why multiplicity affects PAVM recanalization. Last, pulmonary hypertension is a significant predictor of recanalization. We hypothesize this effect is likely due to altered hemodynamics in pulmonary hypertension, the effects of which have not been fully studied in this population.
Limitations of this investigation are mainly related to the limited sample size and the retrospective nature of the study. Analysing anticoagulant and antiplatelet drugs together might have also influenced results, as the results reflect the sum effect and not the individual effects of certain classes or individual drugs. Additionally, the angiographic endpoint for AVM closure may be achieved by a combination of thrombotic and mechanical means (in our institution, patients were not heparinized during embolization). Therefore, there remains the possibility that the effect of postprocedure anticoagulation on recanalization may be different in patients who were heparinized during embolization.
Detailed prospective research is needed with full documentation of medication profiles and duration is required before more specific effects can be elucidated. Additionally, because institution-specific embolization and imaging followup protocols were used, the estimate of recanalization may be biased. For example, magnetic resonance angiography is a new imaging technique that is less sensitive to metal artifact than CT is and offers the advantage of observing lesion hemodynamics [17, 18] . Recent investigations are highlighting the role of noncontrast CT in following up embolized PAVMs, with a sensitivity of 98%-100% [19] . Prospective randomized data will need to be established before these follow-up imaging protocols are incorporated at our institution.
Conclusion
Recanalization (single and recurrent) is associated with antithrombotic use postembolization. Future directions for investigation include examining the natural history of recanalized PAVMs and their effect on stroke risk. Prospective data examining the duration, indications, and method of antithrombotic use in HHT will help elucidate the long-term effects.
Through continued investigation by interventional radiologists and clinicians alike, clinical care of HHT patients with PAVMs should continue to evolve, providing long-term risk reduction while balancing the need for repeat intervention.
